Background: ESBL-producing Escherichia coli have expanded globally since the turn of the century and present a major public health issue. Their in vitro susceptibility to penicillin/inhibitor combinations is variable, and clinical use of these combinations against ESBL producers remains controversial. We hypothesized that this variability related to co-production of OXA-1 penicillinase.
Introduction
Penicillin/b-lactamase inhibitor combinations account for 20% of inpatient antibiotic use in UK hospitals 1 and for a greater proportion of parenteral use. Whilst these combinations are effective in many infections due to b-lactamase producers, debate persists on their efficacy against those with ESBLs, along with disagreements on breakpoints. 2 Tazobactam and clavulanate inhibit TEM, SHV and CTX-M ESBLs, [3] [4] [5] in some cases more efficiently than classical penicillinases. 6 Nevertheless, surveys find that sizeable proportions of ESBL-producing Escherichia coli and Klebsiella pneumoniae are non-susceptible to piperacillin/tazobactam and amoxicillin/clavulanate, as are minorities of isolates with classical TEM and SHV penicillinases. [7] [8] [9] The issue is complicated by differing breakpoints for piperacillin/tazobactam between EUCAST (S 8, R . 16 mg/L) and CLSI (S 16, R . 64 mg/L) and different testing modalities for amoxicillin/clavulanate, where EUCAST advocates a fixed 2 mg/L clavulanate concentration but CLSI prefers a 2:1 amoxicillin/clavulanate ratio, giving breakpoints of 8!2 and 8!4 mg/L, respectively.
Clinical studies on the efficacy of penicillin/inhibitor combinations against ESBL producers have given contradictory results. 10 Both EUCAST and CLSI take the view of 'report as found', 11 and one bacteraemia study (not specifically of ESBL producers) found good outcomes for piperacillin/tazobactam against Enterobacteriaceae up to an MIC of 16 mg/L. 12 Another study, however, found good outcomes up to an MIC of 16 mg/L only if the bacteraemia had a urinary origin whereas there were high failure rates if the MIC was above 2 mg/L and the bacteraemia originated elsewhere. 13 The recent MERINO trial, investigating bacteraemia due to ceftriaxone-resistant, piperacillin/tazobactam-susceptible E. coli and K. pneumoniae found 12.3% 30 day mortality for patients treated with piperacillin/tazobactam versus 3.7% for meropenem (P " 0.002). 14 Reasons for variable resistance to penicillin/inhibitor combinations among ESBL producers are under-researched. Factors demonstrated for at least some isolates include: (i) production of multiple b-lactamases, 15 sometimes including poorly inhibited penicillinases such as OXA-1; 16, 17 (ii) hyperproduction of target blactamases; 18, 19 and (iii) impermeability. 20 We explored the role of the OXA-1 enzyme in a national collection of genomically sequenced ESBL-producing E. coli from bloodstream infections.
Materials and methods

Isolates
Isolates were from human bloodstream infections and were collected in the period 2013-14 during a national study comparing ESBL-producing E. coli from human and non-human sources. Collecting sites in London (one hospital), East Anglia (five hospitals), North-West England (two hospitals), Wales (two hospitals) and Scotland (two hospitals) incubated blood cultures on automated BacT/ALERT (bioMérieux, Basingstoke, UK) systems and performed identification and susceptibility testing according to local protocols. Consecutive isolates identified by these local methods as ESBLproducing E. coli were subcultured to agar slopes and sent to PHE Colindale, London, UK. On receipt, their identity was confirmed by MALDI-TOF MS (Bruker Daltonics, Bremen, Germany) and bla CTX-M genes were sought by PCR, 21 with isolates found positive accepted as ESBL producers. Isolates lacking bla CTX-M were screened for bla TEM and bla SHV by PCR 22 and, if positive, subjected to double-disc synergy tests between amoxicillin/clavulanate (20!10 lg; Oxoid, Basingstoke, UK) and each of cefepime, cefotaxime and ceftazidime (all 30 lg), with a positive result for any cephalosporin being taken to indicate ESBL activity. 23 Confirmation of ESBL production came from comprehensive susceptibility testing and sequencing, as below.
Antibiotics and susceptibility testing
Except for clavulanate (GlaxoSmithKline, Brentford, UK) and tazobactam (Alfa Aesar, Heysham, UK), antibiotics were obtained from Sigma, Poole, UK. MICs were determined by BSAC agar dilution using Iso-Sensitest agar (Oxoid). 24 Tazobactam was used at a fixed concentration of 4 mg/L and clavulanate at a fixed concentration of 2 mg/L, in keeping with current EUCAST guidance.
WGS
DNA libraries were prepared using the Nextera XT method and sequenced to .30% coverage with a standard 2%100 bp protocol on a HiSeq 2500 instrument (Illumina, San Diego, CA, USA). Reads were trimmed using Trimmomatic to remove low-quality data, then assembled into contigs using VelvetOptimiser 25 with k-mer values from 55 to 75. Strains were identified by mapping reads against ST-specific E. coli sequences using MOST software. 26 Antibiotic resistance genes were sought in contigs by BLASTn, or by mapping reads against reference sequences in the Comprehensive Antibiotic Resistance Database and parsing the variant call format (VCF) file generated by SAMtools mpileup. 27 This process was automated into the 'Genefinder' pipeline created by PHE Bioinformatics (M. Doumith, PHE, unpublished data). The location of resistance determinants on assembled contigs was checked by BLASTn.
Statistics
We calculated relative risks and assessed potential interactions using the Woolf test for homogeneity. We used Pearson v 2 tests to assess significance of associations at a P value equal to 0.05.
Results
ESBL confirmation and STs
Sixty-six ESBL producers were confirmed from bacteraemic patients in East Anglia, 55 from London, 61 from North-West England, 37 from Scotland and 74 from Wales, giving a geographically representative collection of 293 isolates. These isolates included 39 known STs, one non-typeable organism and five new STs. The well-known international ST131 lineage 28, 29 dominated, with 188 representatives (64.2%); other STs with more than two representatives were ST38 (n " 17), ST648 (n " 16), ST405 (n " 9), ST73 (n " 6), ST69 (n " 4), ST636 (n " 4), ST95 (n " 3), ST10 (n " 3) and ST1193 (n " 3). CTX-M-15 b-lactamase was the predominant ESBL, with its gene present in 229 (78.2%) isolates, whereas 27 had bla CTX-M-27 , 20 had bla CTX-M-14 , 4 had bla CTX-M-1 , 3 had bla CTX-M-3 and 1 had bla CTX-M-9 . Three isolates had bla SHV-12 and one had bla SHV-31 , both of which encode recognized SHV-ESBLs; one isolate, with an ESBL phenotype, solely had bla TEM-117 and eight, all carrying other well-known ESBL determinants, also had bla , encoding a TEM variant with an uncertain status, which was not counted as an ESBL here. 30 Four isolates carried two ESBL genes in combination; many more also carried genes for classical penicillinases along with those for ESBLs. In particular, bla TEM-1 was present in 129/293 isolates (or 137/293 if those with TEM-191 were included, 46.8%) and bla OXA-1 (or, in one case, a variant with a conservative Ile187Leu modification) was found in 149/293 (50.9%). bla TEM-1 accompanied many different ESBL genes but bla OXA-1 was always together with bla CTX-M-15 along, in one isolate, with bla CTX-M-14 . Two isolates had acquired bla CMY /ampC genes together with their ESBLs, and two had bla OXA-9 . Among the 188 ST131 isolates, the great majority (159/188, 84.6%) had bla CTX-M-15 , though 24 had bla CTX-M-27 and 5 had bla CTX-M-14 alone or in combination; 116 had bla OXA-1 , whilst 76 had bla TEM-1/191 .
The b-lactamase combinations found in the whole collection and among the ST131 isolates are detailed in Table 1 , which also shows the corresponding MIC distributions of piperacillin/tazobactam and amoxicillin/clavulanate.
Whenever bla OXA-1 was present, alone or together with bla TEM-1/191 , the MIC distributions of penicillin/inhibitor combinations were raised, with the mode increasing from 2 mg/L to 8 or (depending on the particular subset) 16 mg/L for piperacillin/tazobactam and from 4 or 8 to 16 mg/L for amoxicillin/clavulanate. These shifts in modal MIC were apparent for both the whole collection and for ST131, when this was reviewed separately. No such shift was seen when ESBLs were accompanied only by TEM-1/191 enzyme.
Whilst these bla OXA-1 -related MIC shifts were small in absolute terms, their effect was to move the peak of the distribution for piperacillin/tazobactam from within the susceptible range to around the breakpoint, whilst the mode for amoxicillin/clavulanate moved across the breakpoint. Overall, 62/63 (98.4%) isolates with ESBL genes alone were susceptible to piperacillin/tazobactam at 8 mg/L, as were 75/79 (94.9%) that had an ESBL gene together with only bla TEM-1/191 , whereas the proportion that were susceptible fell to 67/91 (73.6%) among those with an ESBL plus bla OXA-1 and to 33 Both for the whole collection and the ST131 isolates, the relative risks of non-susceptibility to penicillin/b-lactamase inhibitor combinations were highly significant for OXA-1 (P , 0.001) but non-significant for TEM-1/191 (Table 2 ). Although the modal MIC was one doubling dilution higher for the isolates that had both OXA-1 and TEM-1/191 than for those with only OXA-1, there was no statistical evidence of interaction between OXA-1 and TEM-1/191 to further augment resistance.
Occasional non-susceptibility to piperacillin/tazobactam was seen in isolates lacking bla OXA-1 , as in 1/26 with bla CTX-M-15 alone (MIC 32 mg/L) and 4/65 with bla CTX-M-14/15 together with bla TEM-1 (MICs 16-32 mg/L), also (unsurprisingly) in both isolates with acquired bla CMY genes, neither of which had bla OXA-1 . On the other hand, 10/58 isolates with bla CTX-M-15 plus both bla TEM-1/191 and bla OXA-1 remained fully susceptible to piperacillin/tazobactam, with MICs of 2-4 mg/L.
Linkage of bla OXA-1, aac(6 0 )-Ib and other resistance determinants
There was a striking association between the carriage of bla OXA-1 and of the aminoglycoside acetyltransferase determinant aac(6 0 )-Ib, which was almost always (146/148 cases) present as its aac(6 0 )-Ib-cr variant, encoding an enzyme that acetylates some fluoroquinolones as well as the normal aminoglycoside substrates. This association is illustrated both for the whole collection and for the major b-lactamase-defined subgroups of ST131 isolates in Table 3 . Overall, 147 of the 149 isolates with bla OXA-1 also had aac(6 0 )-Ib-cr, compared with 1/144 of those that lacked bla OXA-1 .
Other resistance genes associated with bla OXA-1 across the whole collection were aac(3)-IIa, aadA5, sul1, dfrA17 and tet(A) ( Table 4) . catB3, encoding a chloramphenicol acetyltransferase, also was widely present in association with bla OXA-1 (not shown) but was truncated and surmised to be non-functional. Conversely, sul2, strA, strB and aac(3)-IId were more prevalent among isolates that lacked bla OXA-1 . The association between bla OXA-1 and aac(6 0 )-Ib-cr remained clear when ST131 isolates were considered alone, but aac(3)-IIa, aadA5, sul1, dfrA17 and tet(A) remained widespread among ST131 isolates with bla CTX-M-27 alone or with bla CTX-M-15 combined with either or both of bla TEM and/or bla OXA-1 . strA/B and sul2 genes remained negatively associated with bla OXA-1 among the ST131 isolates (Table 4) .
Resistance tracked with causative genes. Thus, 141/148 isolates with aac(6 0 )-Ib-cr were resistant to tobramycin and 69 had reduced susceptibility to amikacin, with MICs .4 mg/L, though non-susceptibility according to EUCAST criteria (MIC .8 mg/L) was seen for only 25/148. Tobramycin resistance was not, however, exclusive to isolates with aac(6 0 )-Ib-cr, also being associated with aac(3)-II variants when these were present independently of aac (6 0 
Discussion
Although a link between OXA-1 enzyme and reduced susceptibility or resistance to penicillin/inhibitor combinations has been suggested previously, 16, 17 both for ESBL-producing and -non-producing Enterobacteriaceae, these assertions do not appear to have been tested with sizeable and geographically diverse collections of Livermore et al.
bacteria, let alone using those characterized by WGS. One study asserting this linkage only found OXA-1 in 12/59 piperacillin/ tazobactam-resistant isolates and, since many of the remainder were resistant to carbapenems, it is likely that they had other mechanisms besides OXA-1 enzyme. 16 Here we found that MICs of piperacillin/tazobactam for ESBLproducing E. coli with OXA-1 penicillinase clustered around or just above the 8!4 mg/L breakpoint, and that those of amoxicillin/ clavulanate were narrowly above its 8!2 mg/L breakpoint. By contrast, and irrespective of whether they co-produced TEM-1 enzyme, MICs for ESBL-producing E. coli lacking OXA-1 enzyme were almost all clearly within the susceptible range for piperacillin/ tazobactam, at around 2 mg/L, and narrowly within it for amoxicillin/clavulanate, clustering at 4 to 8 mg/L. A few individual isolates lay outside these generalizations, either: (i) lacking OXA-1 enzyme but being resistant to penicillin/b-lactamase inhibitor combinations; or (ii) possessing the gene for this enzyme and remaining susceptible. Anomalous resistance perhaps may reflect low permeability, up-regulated efflux, copious ESBL production or elevated expression of chromosomal AmpC; anomalous susceptibility may reflect high permeability, weak efflux or non-expression of bla OXA-1 or other genes. Nevertheless, the general relationship between raised MICs of the inhibitor combinations and carriage of bla OXA-1 was clear and individual anomalies were not pursued further.
It should be cautioned that the ESBL accompanying OXA-1 was always CTX-M-15, and we cannot be certain that identical behaviour would be seen with other ESBLs. However, there is no obvious OXA-1 and penicillin/inhibitor resistance JAC reason why the ESBL type should affect the poor inhibition of OXA-1, and CTX-M-15 is considerably the commonest ESBL in the UK and worldwide. 29 In the absence of OXA-1, modal MICs of the penicillin/inhibitor combinations were consistent irrespective of whether CTX-M-15 or another ESBL was produced.
These findings have clear implications for penicillin/inhibitor combinations but not for newer cephalosporin/inhibitor combinations (e.g. ceftolozane/tazobactam and ceftazidime/avibactam), as these use cephalosporins that are stable to OXA-1 enzyme. Cefepime is somewhat labile to OXA-1, 31,32 but prospective cefepime/tazobactam combinations appear to retain near universal activity against ESBL producers, many of which likely also carry OXA-1. 33 The therapeutic challenges posed by bacteria carrying OXA-1 enzyme together with CTX-M-15 are exacerbated by frequent cocarriage of aac(6 0 )-Ib [almost always as its aac(6 0 )-Ib-cr variant], conferring resistance to tobramycin. AAC(6 0 )-Ib also acetylates amikacin and, although MICs for producers commonly remained below the breakpoint, current EUCAST advice remains to avoid the drug wherever this enzyme is present. 11 Resistance rates to ciprofloxacin, sulphonamides, trimethoprim and tetracycline also were slightly higher among OXA-1-positive than OXA-1-negative ESBL producers though, unlike for tobramycin and the penicillin/inhibitor combinations, these resistance rates were high in both groups.
Co-carriage of bla OXA-1 with bla CTX-M-15 has been previously established in UK variants of E. coli ST131, where it was associated with IncF plasmids pEK499 (117 536 bp) and pEK516 (64 471 bp). 34, 35 Plasmid pEK516 had bla OXA-1 and bla CTX-M-15 separated by a 7457 bp region that encoded catB4, aac(3)-IIa and tunicamycin resistance genes; aac(6 0 )-1b-cr was immediately upstream of bla OXA-1 and a class 1 integron containing dfrA17, aadA5 and sul1 genes was present 1.7 kb upstream of bla CTX-M-15 . A similar organization is seen in the common Canadian bla CTX-M-15 plasmid pC15-1a. 36 In the case of pEK499, which differed from pEK516 in having an IS26-mediated deletion of aac(3)-IIa and the tunicamycin resistance genes, bla OXA-1 and bla CTX-M-15 were only 4037 bp apart. Given their earlier prevalence, and the similarity of the present resistance profiles it seems likely that the same or very similar plasmids to pEK499 and pEK516 remain prevalent in bloodstream ST131 E. coli from the UK. This could not be definitively proven here because the presence of multiple copies of IS26 precluded assembly from short-read sequencing data; nevertheless, we could confirm that bla OXA-1 , aac(6 0 )-1b-cr and the truncated catB3 were demonstrably linked on the same 2-3 kb contig in at least 139 of the 149 isolates that had both bla OXA-1 and bla CTX-M-15 .
In conclusion, these data suggest that the frequent question, 'Are penicillin/inhibitor combinations active against ESBL producers?' is misplaced. The more pertinent query is, 'Does my ESBLproducing isolate also have OXA-1 enzyme?' The findings have implications for diagnostic development. We have shown elsewhere that multiplex tandem PCR can be used to seek bacterial resistance genes in urine from urinary tract infection (UTI) patients, giving accurate results 24-48 h before susceptibility test data become available. 37 A panel that targeted E. coli generically, E. coli ST131 specifically, bla OXA-1 , bla CTX-M , aac(6 0 )-1b, common gentamicin resistance determinants and the gyrA mutations responsible for fluoroquinolone resistance has the potential to provide a useful guide for the treatment of patients being admitted to hospital with upper UTIs and urosepsis. Detection of ST131 and the bla OXA-1 , bla CTX-M , aac(6 0 )-Ib-cr trio should give a steer towards early carbapenem use in the severely ill patient, whilst the absence of bla OXA-1 should increase the confidence with which penicillin/inhibitor combinations might be used.
